Access to Genetic Counselor Services Act: H.R. 6280, S. 3607 Living Donor Protection Act: H.R. 4582, H.R 4583, S. 1552 Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2025: H.R. 1518. Restore Protections for Dialysis Patients Act: H.R. 2199; S. 1173. Permanent OPTN Fee Authority Act: H.R.5259; S. 2751. Kidney Care Access Protection Act: S.2730. H.R. 6214 Expanding Support for Living Donors Act: H.R. 7868 Improving Home Dialysis Act: H.R. 8875 CMS-1846-P: Medicare Program; CY 2027 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Acute Kidney Injury Dialysis (AKI) Payment, and ESRD Quality Incentive Program Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program Medicaid Program; Community Engagement Requirement for Certain Individuals (CMS- 2454-IFC); Interim Final Rule with Comment Period
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$220,000
What this organization spent lobbying with its own staff.
Reported using IRS section 6033(b)(8) definitions (method B): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
Maryland
Government bodies contacted
4
Lobbying activity
1